CDK4/6 inhibitors promote PARP1 degradation and act synergistically with PARP inhibitors in non-small cell lung cancer
C. M. Roggero, A. B. Ghosh, A. Devineni, S. Ma, E. Blatt, G. V. Raj, Y. Yin
This study shows CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors to kill NSCLC cells by enhancing DNA damage and apoptosis.
bioRxiv · Jul 7, 2024 · PreprintCancer Biology